astmedАстраханский медицинский журналAstrakhan medical journal1992-6499ФГБОУ ВО Астраханский ГМУ Минздрава России10.17021/1992-6499-2025-2-08-26astmed-553Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSСовременное представление о диагностике кардиотоксичности у пациентов с множественной миеломой при аутологичной трансплантации гемопоэтических стволовых клетокCurrent understanding of cardiotoxicity diagnostics in patients with multiple myeloma during autologous hematopoietic stem cell transplantationhttps://orcid.org/0009-0000-0359-3719ПодсеваловВ. С.PodsevalovV. S.

Владимир Святославович Подсевалов - аспирант кафедры госпитальной терапии с курсами гематологии и трансфузиологии.

Самара

Vladimir S. Podsevalov - Assistant of the Department.

Samara

v.s.podsevalov@mail.ruhttps://orcid.org/0000-0003-0296-4236СабановаВ. Д.SabanovaV. D.

Виктория Давыдовна Сабанова - ассистент кафедры госпитальной терапии с курсами гематологии и трансфузиологии.

Самара

Victoria D. Sabanova - Assistant of the Department.

Samara

v.d.sabanova@samsmu.ruhttps://orcid.org/0000-0003-4833-4563ГермановаО. А.GermanovaO. A.

Ольга Андреевна Германова - доктор медицинских наук, директор МНОЦ кардиоваскулярной патологии и кардиовизуализации, Самарский государственный медицинский университет.

Самара

Olga A. Germanova - Dr. Sci. (Med.), Director of the International Research Center.

Samara

o.a.germanova@samsmu.ruhttps://orcid.org/0000-0002-4318-4247ДавыдкинИ. Л.DavydkinI. L.

Игорь Леонидович Давыдкин - доктор медицинских наук, профессор, заведующий кафедрой госпитальной терапии с курсами гематологии и трансфузиологии, директор НИИ гематологии, трансфузиологии и интенсивной терапии.

Самара

Igor L. Davydkin - Dr. Sci. (Med.), Professor, Head of the Department, Director of the Research Institute.

Samara

i.l.davydkin@samsmu.ruСамарский государственный медицинский университетРоссияSamara State Medical UniversityRussian Federation202515072025202826Copyright © Подсевалов В.С., Сабанова В.Д., Германова О.А., Давыдкин И.Л., 20252025Подсевалов В.С., Сабанова В.Д., Германова О.А., Давыдкин И.Л.Podsevalov V.S., Sabanova V.D., Germanova O.A., Davydkin I.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.astmedj.ru/jour/article/view/553

Рассмотрены современные лабораторные и инструментальные подходы к диагностике кардиоваскулярной токсичности у пациентов с множественной миеломой при аутологичной трансплантации гемопоэтических стволовых клеток. В условиях отсутствия унифицированных национальных рекомендаций по срокам и частоте мониторинга особую клиническую значимость приобретает комплекс диагностических методик, направленный на выявление доклинических форм миокардиальной дисфункции. К числу наиболее информативных методов относятся: трансторакальная эхокардиография с оценкой глобальной продольной деформации методом speckle-tracking, а также определение кардиоспецифических биомаркеров, включая тропонины T и I и натрийуретические пептиды. Применение указанного комплекса диагностических исследований позволяет осуществлять раннюю верификацию кардиотоксических эффектов, что имеет принципиальное значение для своевременной коррекции терапии.

This review presents current laboratory and instrumental methods for cardiovascular toxicity diagnosing in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. In the absence of national guidelines on the timing and frequency of monitoring, it is particularly important to have a set of techniques to detect preclinical stages of myocardial dysfunction. The most useful methods include transthoracic echocardiography, with assessment of global longitudinal strain using speckle tracking, and measurement of cardiac biomarkers such as troponin T and I, and natriuretic peptides. Using this combination of methods allows for early detection of cardiotoxicity, which is essential for timely intervention and treatment.

кардиотоксичностьмножественная миеломааутологичная трансплантация гемопоэтических стволовых клетоктропонинынатрийуретический пептидэхокардиографияглобальная продольная деформация миокардаcardiotoxicitymultiple myelomaautologous hematopoietic stem cell transplantationtroponinsnatriuretic peptidesechocardiographyglobal longitudinal strainАвторы декларируют отсутствие внешнего финансирования для проведения исследования и публикации статьиThe authors declare that there is no external funding for the exploration and analysis workReferencesJain D., Russell R. R., Schwartz R. G., Panjrath G. S., Aronow W. Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions // Current Cardiology Reports. 2017. Vol. 19, no. 5. Art. 36. doi: 10.1007/s11886-017-0846-x.Jain D., Russell R. R., Schwartz R. G., Panjrath G. S., Aronow W. Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions. Current Cardiology Reports. 2017; 19, (5); 36. doi: 10.1007/s11886-017-0846-x.Schlitt A., Jordan K., Vordermark D., Schwamborn J., Langer T., Thomssen C. Cardiotoxicity and oncological treatments // Deutsches Ärzteblatt International. 2014. Vol. 111, no. 10. P. 161–168. doi: 10.3238/arztebl.2014.0161.Schlitt A., Jordan K., Vordermark D., Schwamborn J., Langer T., Thomssen C. Cardiotoxicity and oncological treatments. Deutsches Ärzteblatt International. 2014; 111 (10): 161–168. doi: 10.3238/arztebl.2014.0161.Silver R. T., Woolf S. H., Hehlmann R., Appelbaum F. R., Anderson J., Bennett C., Goldman J. M., Guilhot F., Kantarjian H. M., Lichtin A. E., Talpaz M., Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology // Blood. 1999. Vol. 94, no. 5. P. 1517–1536.Silver R. T., Woolf S. H., Hehlmann R., Appelbaum F. R., Anderson J., Bennett C., Goldman J. M., Guilhot F., Kantarjian H. M., Lichtin A. E., Talpaz M., Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999; 94 (5): 1517–1536.Cortes J. E., Saglio G., Kantarjian H. M., Baccarani M., Mayer J., Boqué C., Shah N. P., Chuah C., Casanova L., Bradley-Garelik B., Manos G., Hochhaus A. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial // Journal of Clinical Oncology. 2016. Vol. 34, no. 20. P. 2333–2340. doi: 10.1200/JCO.2015.64.8899.Cortes J. E., Saglio G., Kantarjian H. M., Baccarani M., Mayer J., Boqué C., Shah N. P., Chuah C., Casanova L., Bradley-Garelik B., Manos G., Hochhaus A. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. Journal of Clinical Oncology. 2016; 34 (20): 2333–2340. doi: 10.1200/JCO.2015.64.8899.Hochhaus A., Saglio G., Hughes T. P., Larson R. A., Kim D. W., Issaragrisil S., le Coutre P. D., Etienne G., Dorlhiac-Llacer P. E., Clark R. E., Flinn I. W., Nakamae H., Donohue B., Deng W., Dalal D., Menssen H. D., Kantarjian H. M. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial // Leukemia. 2016. Vol. 30, no. 5. P. 1044– 1054. doi: 10.1038/leu.2016.5.Hochhaus A., Saglio G., Hughes T. P., Larson R. A., Kim D. W., Issaragrisil S., le Coutre P. D., Etienne G., Dorlhiac-Llacer P. E., Clark R. E., Flinn I. W., Nakamae H., Donohue B., Deng W., Dalal D., Menssen H. D., Kantarjian H. M. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; 30 (5): 1044–1054. doi: 10.1038/leu.2016.5.Eichhorst B., Fink A. M., Bahlo J., Busch R., Kovacs G., Maurer C., Lange E., Köppler H., Kiehl M., Sökler M., Schlag R., Vehling-Kaiser U., Köchling G., Plöger C., Gregor M., Plesner T., Trneny M., Fischer K., Döhner H., Kneba M., Wendtner C. M., Klapper W., Kreuzer K. A., Stilgenbauer S., Böttcher S., Hallek M.; International group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial // The Lancet Oncology. 2016. Vol. 17, no. 7. P. 928–942. doi: 10.1016/S1470-2045(16)30051-1.Eichhorst B., Fink A. M., Bahlo J., Busch R., Kovacs G., Maurer C., Lange E., Köppler H., Kiehl M., Sökler M., Schlag R., Vehling-Kaiser U., Köchling G., Plöger C., Gregor M., Plesner T., Trneny M., Fischer K., Döhner H., Kneba M., Wendtner C. M., Klapper W., Kreuzer K. A., Stilgenbauer S., Böttcher S., Hallek M.; International group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 2016; 17 (7): 928–942. doi: 10.1016/S1470-2045(16)30051-1.Mateos M. V., Sonneveld P., Hungria V., Nooka A. K., Estell J. A., Barreto W. G., Corradini P., Min C., Medvedova E., Weisel K. C., Chiu C., Schecter J., Amin H., Qin X., Qi M., Spencer A. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients with multiple myeloma (MM): four-year update of CASTOR // Journal of Clinical Oncology. 2019. Vol. 37, no. 15, Suppl. P. 8040.Mateos M. V., Sonneveld P., Hungria V., Nooka A. K., Estell J. A., Barreto W. G., Corradini P., Min C., Medvedova E., Weisel K. C., Chiu C., Schecter J., Amin H., Qin X., Qi M., Spencer A. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients with multiple myeloma (MM): four-year update of CASTOR. Journal of Clinical Oncology. 2019; 37 (15); suppl.: 8040.Kravchenko J., Berry M., Arbeev K. Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis // Lung Cancer. 2015. Vol. 88, no. 1. P. 85–93.Kravchenko J., Berry M., Arbeev K. Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. Lung Cancer. 2015; 88 (1): 85–93.Thomas E. D., Lochte H. L., Lu W. C., Ferrebee J. W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy // New England Journal of Medicine. 1957. Vol. 257, no. 1. P. 491–496. doi: 10.1056/nejm195709122571102.Thomas E. D., Lochte H. L., Lu W. C., Ferrebee J. W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. New England Journal of Medicine. 1957; 257 (1): 491–496. doi: 10.1056/nejm195709122571102.Appelbaum F. R., Sullivan K. M., Buckner C. D., Clift R. A., Deeg H. J., Fefer A., Hill R., Mortimer J., Neiman P. E., Sanders J. E., Singer J. E., Stewart P., Storb R. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation // Journal of Clinical Oncology. 1987. Vol. 5, no. 9. P. 1340–1347.Appelbaum F. R., Sullivan K. M., Buckner C. D., Clift R. A., Deeg H. J., Fefer A., Hill R., Mortimer J., Neiman P. E., Sanders J. E., Singer J. E., Stewart P., Storb R. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. Journal of Clinical Oncology. 1987: 5 (9): 1340–1347.Phillips G. L., Reece D. E. Clinical studies of autologous bone marrow transplantation in Hodgkin’s disease // Clinical Haematology. 1986. Vol. 15, no. 1. P. 151–166.Phillips G. L., Reece D. E. Clinical studies of autologous bone marrow transplantation in Hodgkin’s disease. Clinical Haematology. 1986; 15 (1): 151–166.Phelan R., Chen M., Bupp C., Bolon Y. T., Broglie L., Brunner-Grady J., Burns L. J., Chhabra S., Christianson D., Cusatis R., Devine S. M., D'Souza A., Eapen M., Hamadani M., Hengen M., Lee S. J., Moskop A., Page K. M., Pasquini M., Pérez W. S., Riches M., Rizzo D., Saber W., Spellman S. R., Stefanski H. E., Steinert P., Weisdorf D., Horowitz M., Auletta J. J., Shaw B. E., Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes // Transplant Cell Therapy. 2022. Vol 28 (7). P. 409.e1–409.e10. doi: 10.1016/j.jtct.2022.04.012.Phelan R., Chen M., Bupp C., Bolon Y. T., Broglie L., Brunner-Grady J., Burns L. J., Chhabra S., Christianson D., Cusatis R., Devine S. M., D'Souza A., Eapen M., Hamadani M., Hengen M., Lee S. J., Moskop A., Page K. M., Pasquini M., Pérez W. S., Riches M., Rizzo D., Saber W., Spellman S. R., Stefanski H. E., Steinert P., Weisdorf D., Horowitz M., Auletta J. J., Shaw B. E., Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Therapy. 2022; 28 (7): 409.e1–409.e10. doi: 10.1016/j.jtct.2022.04.012.Масчан М. А., Скоробогатова Е. В., Шелихова Л. Н., Балашов Д. Н., Благонравова О. Л., Долгополов И. С., Субботина Н. Н., Вахонина Л. В., Фечина Л.Г., Менткевич Г.Л., Паина О. В., Геворгян А. Г., Быкова Т. А., Диникина Ю. В., Субора А. Ю., Бронин Г. О., Алянский А. Л., Новичкова Г. А., Масчан А. А., Зубаровская Л. С. Трансплантация гемопоэтических стволовых клеток у детей в России: краткий обзор активности в 2015–2018 гг. // Вопросы гематологии / онкологии и иммунопатологии в педиатрии. 2020. Т. 19, № 2. С. 22–29.Maschan M. A., Skorobogatova E. V., Shelikhova L. N., Balashov D. N., Blagonravova O. L., Dolgopolov I. S., Subbotina N. N., Vakhonina L. V., Fechina L.G., Mentkevich G.L., Paina O. V., Gevorgian A. G., Bykova T. A., Dinikina Iu. V., Subora A. Iu., Bronin G. O., Alianskii A. L., Novichkova G. A., Maschan A. A., Zubarovskaia L. S. Hematopoietic stem cell transplantation in children in Russia: a brief overview of activity in 2015– 2018. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2020; 19 (2): 22–29. (In Russ.).Кострома И. И., Жернякова А. А., Запреева И. М., Сидорова Ж. Ю., Семенова Н. Ю., Карягина Е. В., Степченкова Е. И., Бессмельцев С. С., Чечеткин А. В., Грицаев С. В. Ретроспективный анализ выживаемости больных множественной миеломой после трансплантации аутологичных гемопоэтических стволовых клеток // Клиническая онкогематология. 2021. Т. 14, № 1. С. 73–79.Kostroma I. I., Zherniakova A. A., Zapreeva I. M., Sidorova Zh. Iu., Semenova N. Iu., Kariagina E. V., Stepchenkova E. I., Bessmeltcev S. S., Chechetkin A. V., Gritcaev S. V. A retrospective analysis of the survival of patients with multiple myeloma after autologous hematopoietic stem cell transplantation. Klinicheskaia onkogematologiia = Clinical oncohematology. 2021; 14 (1): 73–79. (In Russ.).Olson T. L., Pollack M. M., Dávila Saldaña B. J., Patel A. K. Hospital survival following pediatric HSCT: changes in complications, ICU therapies and outcomes over 10 years // Frontiers in Pediatrics. 2023. Vol. 11. Art. 1247792. doi: 10.3389/fped.2023.1247792.Olson T. L., Pollack M. M., Dávila Saldaña B. J., Patel A. K. Hospital survival following pediatric HSCT: changes in complications, ICU therapies and outcomes over 10 years. Frontiers in Pediatrics. 2023; 11; 1247792. doi: 10.3389/fped.2023.1247792.Bhatia S., Dai C., Landier W., Hageman L., Wu J., Schlichting E., Siler A., Funk E., Hicks J., Lim S., Balas N., Bosworth A., Te H. S., Francisco L., Bhatia R., Salzman D., Goldman F. D., Forman S. J., Weisdorf D. J., Wong F. L., Armenian S. H., Arora M. Trends in late mortality and life expectancy after autologous blood or marrow transplantation over three decades: a BMTSS report // Journal of Clinical Oncology. 2022. Vol. 40. P. 1991–2003. doi: 10.1200/JCO.21.02372.Bhatia S., Dai C., Landier W., Hageman L., Wu J., Schlichting E., Siler A., Funk E., Hicks J., Lim S., Balas N., Bosworth A., Te H. S., Francisco L., Bhatia R., Salzman D., Goldman F. D., Forman S. J., Weisdorf D. J., Wong F. L., Armenian S. H., Arora M. Trends in late mortality and life expectancy after autologous blood or marrow transplantation over three decades: a BMTSS report. Journal of Clinical Oncology. 2022; 40: 1991–2003. doi: 10.1200/JCO.21.02372.Baker J. K., Shank-Coviello J., Zhou B., Dixon J., McCorkle R., Sarpong D., Medoff E., Cooper D., Seropian S., Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat // Clinical Lymphoma, Myeloma & Leukemia. 2020. Vol. 20, no. 4. P. 244–251.e4. doi: 10.1016/j.clml.2019.12.027.Baker J. K., Shank-Coviello J., Zhou B., Dixon J., McCorkle R., Sarpong D., Medoff E., Cooper D., Seropian S., Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat. Clinical Lymphoma, Myeloma & Leukemia. 2020; 20 (4): 244–251.e4. doi: 10.1016/j.clml.2019.12.027.Gent D. G., Saif M., Dobson R., Wright D. J. Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults: JACC: CardioOncology State of the Art Review // JACC: CardioOncology. 2024. Vol. 6, no. 4. P. 475–495. doi: 10.1016/j.jaccao.2024.06.004.Gent D. G., Saif M., Dobson R., Wright D. J. Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults: JACC: CardioOncology State of the Art Review. JACC: CardioOncology. 2024; 6 (4): 475–495. DOI: 10.1016/j.jaccao.2024.06.004.Krishan S., Asad Z. U. A., Quiroga D., Ghazi S. M., Quartermaine C., Braunstein Z., Kola-Kehinde O., Shaaban A., Habib A., Khan S., Cheng R., Brammer J. E., Addison D. Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample // Scientific Reports. 2024. Vol. 14. Art. 16829. doi: 10.1038/s41598-024-65294-9.Krishan S., Asad Z. U. A., Quiroga D., Ghazi S. M., Quartermaine C., Braunstein Z., Kola-Kehinde O., Shaaban A., Habib A., Khan S., Cheng R., Brammer J. E., Addison D. Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample. Scientific Reports. 2024; 14; 16829. doi: 10.1038/s41598024-65294-9.Vasbinder A., Hoeger C. W., Catalan T., Anderson E., Chu C., Kotzin M., Xie J., Kaakati R., Berlin H. P., Shadid H., Perry D., Pan M., Takiar R., Padalia K., Mills J., Meloche C., Bardwell A., Rochlen M., Blakely P., Leja M., Banerjee M., Riwes M., Magenau J., Anand S., Ghosh M., Pawarode A., Yanik G., Nathan S., Maciejewski J., Okwuosa T., Hayek S. S. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors // JACC: CardioOncology. 2023. Vol. 5, no. 6. P. 821-832. doi: 10.1016/j.jaccao.2023.07.007.Vasbinder A., Hoeger C. W., Catalan T., Anderson E., Chu C., Kotzin M., Xie J., Kaakati R., Berlin H. P., Shadid H., Perry D., Pan M., Takiar R., Padalia K., Mills J., Meloche C., Bardwell A., Rochlen M., Blakely P., Leja M., Banerjee M., Riwes M., Magenau J., Anand S., Ghosh M., Pawarode A., Yanik G., Nathan S., Maciejewski J., Okwuosa T., Hayek S. S. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors. JACC: CardioOncology. 2023; 5 (6): 821–832. doi: 10.1016/j.jaccao.2023.07.007.Mandala E., Lafara K., Kokkinovasilis D., Kalafatis I., Koukoulitsa V., Katodritou E., Lafaras C. Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review // Life. 2024. Vol. 14. Art. 524. doi: 10.3390/life14040524.Mandala E., Lafara K., Kokkinovasilis D., Kalafatis I., Koukoulitsa V., Katodritou E., Lafaras C. Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review. Life. 2024; 14; 524. doi: 10.3390/life14040524.Alizadehasl A., Ghadimi N., Hosseinifard H., Roudini K., Emami A. H., Ghavamzadeh A., Khoda-Amorzideh D. Cardiovascular diseases in patients after hematopoietic stem cell transplantation: systematic review and meta-analysis // Current Research in Translational Medicine. 2023. Vol. 71, no. 1. Art. 103363. doi: 10.1016/j.retram.2022.103363.Alizadehasl A., Ghadimi N., Hosseinifard H., Roudini K., Emami A. H., Ghavamzadeh A., KhodaAmorzideh D. Cardiovascular diseases in patients after hematopoietic stem cell transplantation: systematic review and meta-analysis. Current Research in Translational Medicine. 2023; 71 (1); 103363. doi: 10.1016/j.retram.2022.103363.Hayek S. S., Zaha V. G., Bogle C., Deswal A., Langston A., Rotz S., Vasbinder A., Yang E., Okwuosa T., American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine, the Council on Cardiovascular and Stroke Nursing. Cardiovascular management of patients undergoing hematopoietic stem cell transplantation: from pretransplantation to survivorship: a scientific statement from the American Heart Association // Circulation. 2024. Vol. 149, no. 16. P. e1113–e1127. doi: 10.1161/CIR.0000000000001220.Hayek S. S., Zaha V. G., Bogle C., Deswal A., Langston A., Rotz S., Vasbinder A., Yang E., Okwuosa T., American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine, the Council on Cardiovascular and Stroke Nursing. Cardiovascular management of patients undergoing hematopoietic stem cell transplantation: from pretransplantation to survivorship: a scientific statement from the American Heart Association. Circulation. 2024; 149 (16): e1113–e1127. doi: 10.1161/CIR.0000000000001220.Yin X., Fan F., Zhang B., Hu Y., Sun C. Cardiovascular-specific mortality among multiple myeloma patients: a population-based study // Therapeutic Advances in Hematology. 2022. Vol. 13. Art. 20406207221086755. doi: 10.1177/20406207221086755.Yin X., Fan F., Zhang B., Hu Y., Sun C. Cardiovascular-specific mortality among multiple myeloma patients: a population-based study. Therapeutic Advances in Hematology. 2022; 13; 20406207221086755. doi: 10.1177/20406207221086755.Lyon A. R., López-Fernández T., Couch L. S., Asteggiano R., Aznar M. C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D. J., de Azambuja E., de Boer R. A., Dent S. F., Farmakis D., Gevaert S. A., Gorog D. A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S. S., Stephens R., Suter T. M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C. G., van der Meer P., van der Pal H. J. H., ESC Scientific Document Group 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) // European Heart Journal. 2022. Vol. 43, no. 41. P. 4229–4361. doi: 10.1093/eurheartj/ehac244.Lyon A. R., López-Fernández T., Couch L. S., Asteggiano R., Aznar M. C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D. J., de Azambuja E., de Boer R. A., Dent S. F., Farmakis D., Gevaert S. A., Gorog D. A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S. S., Stephens R., Suter T. M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C. G., van der Meer P., van der Pal H. J. H., ESC Scientific Document Group 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International CardioOncology Society (IC-OS). European Heart Journal. 2022; 43 (41): 4229–4361. doi: 10.1093/eurheartj/ehac244.Савченко В. Г., Менделеева Л. П., Паровичникова Е. Н. и др. Трансплантация аутологичных гемопоэтических стволовых клеток при гемобластозах: методическое руководство. Москва, 2020. С. 96.Savchenko V. G., Mendeleeva L. P., Parovichnikova E. N. i dr. Autologous hematopoietic stem cell transplantation in hemoblastosis: a methodological guide. Moscow: 2020: 96 p. (In Russ.).Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Москва, 2025. 89 с.Multiple myeloma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Moscow: 2025: 89 p. (In Russ.).Данилова О. Е., Гиматдинова Г. Р., Давыдкин И. Л., Терешина О. В., Сабанова В. Д., Давыдкин Г. И. Новые подходы к оценке сердечно-сосудистой токсичности у пациентов с гематологическими злокачественными опухолями (обзор литературы) // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2023. Т. 16, № 3. С. 331–336.Danilova O. E., Gimatdinova G. R., Davydkin I. L., Tereshina O. V., Sabanova V. D., Davydkin G. I. New approaches to the assessment of cardiovascular toxicity in patients with hematological malignant tumors (review). Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaia praktika = Clinical oncohematology. Fundamental research and clinical practice. 2023; 16 (3): 331–336 (In Russ.).Sabanova V. D., Naumova K. V., Cherenova S. G., Davydkin I. L. Endothelial dysfunction in patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors // Clinical Oncohematology. Fundamental Research and Clinical Practice. 2024. Vol. 17, no. S3. P. 72–73.Sabanova V. D., Naumova K. V., Cherenova S. G., Davydkin I. L. Endothelial dysfunction in patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors. Clinical Oncohematology. Fundamental Research and Clinical Practice. 2024; 17 (S3): 72–73.Черенова С. Г., Наумова К. В., Давыдкин И. Л., Степанова Т. Ю., Сабанова В. Д. Применение бозутиниба для лечения пациентов с хроническим миелолейкозом и его влияние на сердечно-сосудистую систему (литературный обзор) // Бюллетень медицинской науки. 2023. № 1. С. 141–146. doi: 10.31684/25418475-2023-1-141.Cherenova S. G., Naumova K. V., Davydkin I. L., Stepanova T. Iu., Sabanova V. D. Use of Bosutinib for the Treatment of Patients with Chronic Myeloid Leukemia and Its Impact on the Cardiovascular System (review). Byulleten meditcinskoy nauki = Bulletin of medical science. 2023; 1: 141–146. doi: 10.31684/25418475-2023-1-141 (In Russ.).Rotz S. J., Ryan T. D., Jodele S., Jefferies J. L., Lane A., Pate A., Hirsch R., Hlavaty J., Levesque A. E., Taylor M. D., Cash M., Myers K. C., El-Bietar J. A., Davies S. M., Dandoy C. E. The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults // Bone Marrow Transplantation. 2017. Vol. 52, no. 8. P. 1171–1179. doi: 10.1038/bmt.2017.62.Rotz S. J., Ryan T. D., Jodele S., Jefferies J. L., Lane A., Pate A., Hirsch R., Hlavaty J., Levesque A. E., Taylor M. D., Cash M., Myers K. C., El-Bietar J. A., Davies S. M., Dandoy C. E. The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults. Bone Marrow Transplantation. 2017; 52 (8): 1171–1179. doi: 10.1038/bmt.2017.62.Потемкина Н. А. Кардиоваскулярные методы исследования в оценке риска высокодозной химиотерапии и трансплантации гемопоэтических стволовых клеток у пациентов с гемобластозами: автореф. дис. канд. мед. наук. Москва, 2024. 24 с.Potemkina N. A. Cardiovascular research methods in assessing the risk of high-dose chemotherapy and hematopoietic stem cell transplantation in patients with hemoblastosis: Abstract of thesis of Candidate of Medical Sciences. Moscow: 2024: 24 p. (In Russ.).Саржевский В. О., Колесникова Д. С., Мельниченко В. Я. Биохимические маркеры кардиотоксичности высокодозной химиотерапии с аутологичной трансплантацией гемопоэтических стволовых клеток при злокачественных лимфопролиферативных заболеваниях // Клиническая онкогематология. 2016. Т. 9, № 4. С. 465–473.Sarzhevskii V. O., Kolesnikova D. S., Melnichenko V. Ia. Biochemical markers of cardiotoxicity of highdose chemotherapy with autologous hematopoietic stem cell transplantation in malignant lymphoproliferative diseases. Klinicheskaia onkogematologiia = Clinical oncohematology. 2016; 9 (4): 465–473 (In Russ.).Колесникова Д. С. Оценка кардиотоксических эффектов высокодозной химиотерапии с трансплантацией аутологичных стволовых кроветворных клеток при злокачественных лимфомах: автореф. дис. канд. мед. наук. Москва, 2017. 25 с.Kolesnikova D. S. Assessment of cardiotoxic effects of high-dose chemotherapy with autologous hematopoietic stem cell transplantation in malignant lymphomas: Abstract of thesis of Candidate of Medical Sciences. Moscow: 2017. 25 p. (In Russ.).Uchida K., Yuan X., McArthur J., Lassiter R., Pan H., Keerthi D., Tsai K., Avent Y., Hines M., Martinez H. R., Qudeimat A., Ghafoor S. Elevation of NT-proBNP levels in pediatric and young adult hematopoietic stem cell transplant patients with endotheliopathy // Pediatric Reports. 2024. Vol. 16, no. 4. P. 934–944. doi: 10.3390/pediatric16040080.Uchida K., Yuan X., McArthur J., Lassiter R., Pan H., Keerthi D., Tsai K., Avent Y., Hines M., Martinez H. R., Qudeimat A., Ghafoor S. Elevation of NT-proBNP levels in pediatric and young adult hematopoietic stem cell transplant patients with endotheliopathy. Pediatric Reports. 2024; 16 (4): 934–944. doi: 10.3390/pediatric16040080.Roziakova L., Bojtarova E., Mistrik M., Dubrava J., Gergel J., Lenkova N., Mladosievicova B. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation // Journal of Experimental & Clinical Cancer Research. 2012. Vol. 31. Art. 13. doi: 10.1186/1756-9966-31-13.Roziakova L., Bojtarova E., Mistrik M., Dubrava J., Gergel J., Lenkova N., Mladosievicova B. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. Journal of Experimental & Clinical Cancer Research. 2012; 31; 13. doi: 10.1186/1756-9966-31-13.Se Z., Zhou H., Li H., Sun J., Zhan Q., Zeng Q., Liu Q., Xu D. Clinical characteristics of patients with different N-terminal probrain natriuretic peptide levels after hematopoietic stem cell transplantation // Disease Markers. 2020. Art. 8839336. doi: 10.1155/2020/8839336.Se Z., Zhou H., Li H., Sun J., Zhan Q., Zeng Q., Liu Q., Xu D. Clinical characteristics of patients with different N-terminal probrain natriuretic peptide levels after hematopoietic stem cell transplantation. Disease Markers. 2020; 8839336. doi: 10.1155/2020/8839336.Чаулин А. М., Григорьева Ю. В. Основные аспекты биохимии, физиологии сердечных тропонинов // Международный научно-исследовательский журнал. 2020. № 6 (96). С. 129–133. doi: 10.23670/IRJ.2020.96.6.064.Chaulin A. M., Grigoreva Iu. V. The main aspects of biochemistry and physiology of cardiac troponins. // Mezhdunarodnyy nauchno-issledovatelskiy zhurnal = International Research Journal. 2020; 6 (96): 129–133. doi: 10.23670/IRJ.2020.96.6.064 (In Russ.).Cardinale D., Iacopo F., Cipolla C. M. Cardiotoxicity of Anthracyclines // Frontiers in Cardiovascular Medicine. 2020. Vol. 7. Art. 26. doi: 10.3389/fcvm.2020.00026.Cardinale D., Iacopo F., Cipolla C. M. Cardiotoxicity of Anthracyclines. Frontiers in Cardiovascular Medicine. 2020; 7; 26. doi: 10.3389/fcvm.2020.00026.Chauin A. The Main Causes and Mechanisms of Increase in Cardiac Troponin Concentrations Other Than Acute Myocardial Infarction (Part 1): Physical Exertion, Inflammatory Heart Disease, Pulmonary Embolism, Renal Failure, Sepsis // Vascular Health and Risk Management. 2021. Vol. 17. P. 601–617. doi: 10.2147/VHRM.S327661.Chauin A. The Main Causes and Mechanisms of Increase in Cardiac Troponin Concentrations Other Than Acute Myocardial Infarction (Part 1): Physical Exertion, Inflammatory Heart Disease, Pulmonary Embolism, Renal Failure, Sepsis. Vascular Health and Risk Management. 2021; 17: 601–617. doi: 10.2147/VHRM.S327661.Michel L., Mincu R. I., Mahabadi A. A., Settelmeier S., Al-Rashid F., Rassaf T., Totzeck M. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta-analysis // European Journal of Heart Failure. 2020. Vol. 22. P. 350–361. doi: 10.1002/ejhf.1631.Michel L., Mincu R. I., Mahabadi A. A., Settelmeier S., Al-Rashid F., Rassaf T., Totzeck M. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta-analysis. European Journal of Heart Failure. 2020; 22: 350–361. doi: 10.1002/ejhf.1631.de Almeida L. B., Laterza M. C., Rondon M. U. P. B., Toschi-Dias E., de Matos L. D. N. J., Oliveira C. C., Trevizan P. F., Martinez D. G. High-dose chemotherapy impairs cardiac autonomic control of hospitalized cancer patients undergoing autologous hematopoietic stem cell transplantation // Clinical Lymphoma, Myeloma and Leukemia. 2023. Vol. 23, no. 3. P. e131–e138. doi: 10.1016/j.clml.2022.12.010.de Almeida L. B., Laterza M. C., Rondon M. U. P. B., Toschi-Dias E., de Matos L. D. N. J., Oliveira C. C., Trevizan P. F., Martinez D. G. High-dose chemotherapy impairs cardiac autonomic control of hospitalized cancer patients undergoing autologous hematopoietic stem cell transplantation. Clinical Lymphoma, Myeloma and Leukemia. 2023; 23 (3): e131–e138. doi: 10.1016/j.clml.2022.12.010.Jones M., O'Gorman P., Kelly C., Mahon N., Fitzgibbon M. C. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury // Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2017. Vol. 54, no. 1. P. 149–157. doi: 10.1177/0004563216650464.Jones M., O'Gorman P., Kelly C., Mahon N., Fitzgibbon M. C. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2017; 54 (1): 149–157. doi: 10.1177/0004563216650464.Лёвина В. Д., Полтавская М. Г., Чомахидзе П. Ш., Мещеряков А. А., Болотина Л. В., Дешкина Т. И., Валиулина Д. С., Герасимов А. Н., Андреева О. В., Шмелёва А. А., Фашафша З., Левшина А. Р., Седов В. П. Высокочувствительный тропонин I как предиктор дисфункции левого желудочка при применении кардиотоксичных противоопухолевых препаратов для лечения рака молочной железы у больных с преимущественно низким и промежуточным риском кардиотоксичности // Российский кардиологический журнал. 2022. Т. 27, № 11. С. 5210. doi: 10.15829/1560-4071-2022-5210.Levina V. D., Poltavskaia M. G., Chomakhidze P. Sh., et al. Highly sensitive troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer drugs for the treatment of breast cancer in patients with a predominantly low and intermediate risk of cardiotoxicity. Rossiiskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022; 27 (11): 5210. doi: 10.15829/1560-4071-2022-5210 (In Russ.).Lv X., Pan C., Guo H., Chang J., Gao X., Wu X., Zhi X., Ren C., Chen Q., Jiang H., Zhao X., Liu K., Li Y. Early diagnostic value of high-sensitivity cardiac troponin T for cancer treatment-related cardiac dysfunction: a metaanalysis // ESC Heart Failure. 2023. Vol. 10, no. 4. P. 2170–2182. doi: 10.1002/ehf2.14373.Lv X., Pan C., Guo H., Chang J., Gao X., Wu X., Zhi X., Ren C., Chen Q., Jiang H., Zhao X., Liu K., Li Y. Early diagnostic value of high-sensitivity cardiac troponin T for cancer treatment-related cardiac dysfunction: a metaanalysis. ESC Heart Failure. 2023; 10 (4): 2170–2182. doi: 10.1002/ehf2.14373.Gangaraju R., Chen Y., Hageman L., Landier W., Balas N., Ross E., Francisco L., Bosworth A., Te H. S., Wong F. L., Weisdorf D. J., Bhatia R., Forman S. J., Armenian S. H., Bhatia S. Prediction of coronary heart disease events in blood or marrow transplantation recipients // JACC: CardioOncology. 2023. Vol. 5, no. 4. P. 504–517. doi: 10.1016/j.jaccao.2023.03.013.Gangaraju R., Chen Y., Hageman L., Landier W., Balas N., Ross E., Francisco L., Bosworth A., Te H. S., Wong F. L., Weisdorf D. J., Bhatia R., Forman S. J., Armenian S. H., Bhatia S. Prediction of coronary heart disease events in blood or marrow transplantation recipients. JACC: CardioOncology. 2023; 5 (4): 504–517. doi: 10.1016/j.jaccao.2023.03.013.Suzuki T., Hayashi D., Yamazaki T., Mizuno T., Kanda Y., Komuro I., Kurabayashi M., Yamaoki K., Mitani K., Hirai H., Nagai R., Yazaki Y. Elevated B-type natriuretic peptide levels after anthracycline administration // American Heart Journal. 1998. Vol. 136, no. 2. P. 362–363. doi: 10.1053/hj.1998.v136.89908.Suzuki T., Hayashi D., Yamazaki T., Mizuno T., Kanda Y., Komuro I., Kurabayashi M., Yamaoki K., Mitani K., Hirai H., Nagai R., Yazaki Y. Elevated B-type natriuretic peptide levels after anthracycline administration. American Heart Journal. 1998; 136 (2): 362–363. doi: 10.1053/hj.1998.v136.89908.Hall C. NT-ProBNP: the mechanism behind the marker // Journal of Cardiac Failure. 2005. Vol. 11, no. 5. P. S81–S83. doi: 10.1016/j.cardfail.2005.04.019.Hall C. NT-ProBNP: the mechanism behind the marker. Journal of Cardiac Failure. 2005; 11 (5): S81–S83. doi: 10.1016/j.cardfail.2005.04.019.Галявич А. С., Терещенко С. Н., Ускач Т. М., Агеев Ф. Т., Аронов Д. М., Арутюнов Г. П., Беграмбекова Ю. Л., Беленков Ю. Н., Бойцов С. А., Бубнова М. Г., Васюк Ю. А., Виллевальде С. В., Виноградова Н. Г., Гарганеева А. А., Гендлин Г. Е., Гиляревский С. Р., Глезер М. Г., Готье С. В., Гринштейн Ю. И., Довженко Т. В., Драпкина О. М., Дупляков Д. В., Жиров И. В., Затейщиков Д. А., Звартау Н. Э., Иртюга О. Б., Кобалава Ж. Д., Козиолова Н. А., Коротеев А. В., Либис Р. А., Лопатин Ю. М., Мареев В. Ю., Мареев Ю. В., Мацкеплишвили С. Т., Михайлов Е. Н., Насонова С. Н., Нарусов О. Ю., Недогода С. В., Недошивин А. О., Овчинников А. Г., Орлова Я. А., Перепеч Н. Б., Погосова Н. В., Римская Е. М., Самко А. Н., Саидова М. А., Сапельников О. В., Сафиуллина А. А., Ситникова М. Ю., Скворцов А. А., Скибицкий В. В., Стукалова О. В., Тарловская Е. И., Терещенко А. С., Чесникова А. И., Федотов П. А., Фомин И. В., Хасанов Н. Р., Шевченко А. О., Шапошник И. И., Шария М. А., Шляхто Е. В., Явелов И. С., Якушин С. С. Хроническая сердечная недостаточность. Клинические рекомендации 2024 // Российский кардиологический журнал. 2024. Т. 29, № 11. С. 6162. doi: 10.15829/1560-4071-2024-6162.Galiavich A. S., Tereshchenko S. N., Uskach T. M., et al. Chronic heart failure. Clinical guidelines for 2024. Rossiiskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024; 29 (11): 6162. doi: 10.15829/1560-4071-2024-6162 (In Russ.).Madamanchi C., Alhosaini H., Sumida A., Runge M. S. Obesity and natriuretic peptides, BNP and NTproBNP: mechanisms and diagnostic implications for heart failure // International Journal of Cardiology. 2014. Vol. 176, no. 3. P. 611–617. doi: 10.1016/j.ijcard.2014.08.007.Madamanchi C., Alhosaini H., Sumida A., Runge M. S. Obesity and natriuretic peptides, BNP and NTproBNP: mechanisms and diagnostic implications for heart failure. International Journal of Cardiology. 2014; 176 (3): 611–617. doi: 10.1016/j.ijcard.2014.08.007.Kumar L., Vijayvergiya R., Jain A., Singh C., Jain A., Prakash G., Khadwal A., Malhotra P. Incidence, risk factors and early prediction of doxorubicin-induced cardiotoxicity by global longitudinal strain and cardiac biomarkers in Indian patients with lymphoma: a prospective observational study // Clinical Lymphoma, Myeloma and Leukemia. 2025. Vol. 25, no. 3. P. e143–e150.Kumar L., Vijayvergiya R., Jain A., Singh C., Jain A., Prakash G., Khadwal A., Malhotra P. Incidence, risk factors and early prediction of doxorubicin-induced cardiotoxicity by global longitudinal strain and cardiac biomarkers in Indian patients with lymphoma: a prospective observational study. Clinical Lymphoma, Myeloma and Leukemia. 2025; 25 (3): e143–e150.Poręba M., Gać P., Usnarska-Zubkiewicz L., Pilecki W., Kuliczkowski K., Mazur G., Gonerska M., Sobieszczańska M., Poręba R. Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies // Medical Oncology. 2018. Vol. 35, no. 12. Art. 162. doi: 10.1007/s12032-018-1221-5.Poręba M., Gać P., Usnarska-Zubkiewicz L., Pilecki W., Kuliczkowski K., Mazur G., Gonerska M., Sobieszczańska M., Poręba R. Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies. Medical Oncology. 2018; 35 (12); 162. doi: 10.1007/s12032-018-1221-5.Attanasio U., Di Sarro E., Tricarico L., Di Lisi D., Armentaro G., Miceli S., Fioretti F., Deidda M., Correale M., Novo G., Sciacqua A., Nodari S., Cadeddu C., Tocchetti C. G., Palazzuoli A., Mercurio V. Cardiovascular biomarkers in cardio-oncology: antineoplastic drug cardiotoxicity and beyond // Biomolecules. 2024. Vol. 14, no. 2. Art. 199. doi: 10.3390/biom14020199.Attanasio U., Di Sarro E., Tricarico L., Di Lisi D., Armentaro G., Miceli S., Fioretti F., Deidda M., Correale M., Novo G., Sciacqua A., Nodari S., Cadeddu C., Tocchetti C. G., Palazzuoli A., Mercurio V. Cardiovascular biomarkers in cardio-oncology: antineoplastic drug cardiotoxicity and beyond. Biomolecules. 2024; 14 (2): 199. doi: 10.3390/biom14020199.Murtagh G., Januzzi J. L., Scherrer-Crosbie M., Neilan T. G., Dent S., Ho J. E., Appadurai V., McDermott R., Akhter N. Circulating cardiovascular biomarkers in cancer therapeutics-related cardiotoxicity: review of critical challenges, solutions, and future directions // Journal of the American Heart Association. 2023. Vol. 12, no. 21. Art. e029574. doi: 10.1161/JAHA.123.029574.Murtagh G., Januzzi J. L., Scherrer-Crosbie M., Neilan T. G., Dent S., Ho J. E., Appadurai V., McDermott R., Akhter N. Circulating cardiovascular biomarkers in cancer therapeutics-related cardiotoxicity: review of critical challenges, solutions, and future directions. Journal of the American Heart Association. 2023; 12 (21): e029574. doi: 10.1161/JAHA.123.029574.Joolharzadeh P., Rodriguez M., Zaghlol R., Pedersen L. N., Jimenez J., Bergom C., Mitchell J. D. Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology // Current Cardiology Reports. 2023. Vol. 25, no. 3. P. 133–146. doi: 10.1007/s11886-022-01834-x.Joolharzadeh P., Rodriguez M., Zaghlol R., Pedersen L. N., Jimenez J., Bergom C., Mitchell J. D. Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology. Current Cardiology Reports. 2023; 25 (3): 133–146. doi: 10.1007/s11886-022-01834-x.Graf I., Greiner G., Marculescu R., Gleixner K. V., Herndlhofer S., Stefanzl G., Knoebl P., Jäger U., Hauswirth A., Schwarzinger I., Thalhammer R., Kundi M., Hoermann G., Mitterbauer-Hohendanner G., Valent P., Sperr W. R. N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia // American Journal of Hematology. 2023. Vol. 98, no. 2. P. 290–299. doi: 10.1002/ajh.26805.Graf I., Greiner G., Marculescu R., Gleixner K. V., Herndlhofer S., Stefanzl G., Knoebl P., Jäger U., Hauswirth A., Schwarzinger I., Thalhammer R., Kundi M., Hoermann G., Mitterbauer-Hohendanner G., Valent P., Sperr W. R. N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. American Journal of Hematology. 2023; 98 (2): 290–299. doi: 10.1002/ajh.26805.Habibollahzadeh N., Yavari S., Mirazimi Y., Aghayan A. H., Davoudian A., Rafiee M. MicroRNAs utilization as effective factors on hematopoietic stem cell transplantation, its outcomes and prognosis; a comprehensive systematic review // BMC Cancer. 2024. Vol. 24. Art. 890. doi: 10.1186/s12885-024-12640-9.Habibollahzadeh N., Yavari S., Mirazimi Y., Aghayan A. H., Davoudian A., Rafiee M. MicroRNAs utilization as effective factors on hematopoietic stem cell transplantation, its outcomes and prognosis; a comprehensive systematic review. BMC Cancer. 2024; 24; 890. doi: 10.1186/s12885-024-12640-9.Moscoso I., Rodríguez-Mañero M., Cebro-Márquez M., Vilar-Sánchez M. E., Serrano-Cruz V., Vidal-Abeijón I., Martínez-Monzonís M. A., Mazón-Ramos P., Pedreira M., González-Juanatey J. R., Lage R. Transforming cardiotoxicity detection in cancer therapies: the promise of microRNAs as precision biomarkers // International Journal of Molecular Sciences. 2024. Vol. 25, no. 22. Art. 11910. doi: 10.3390/ijms252211910.Moscoso I., Rodríguez-Mañero M., Cebro-Márquez M., Vilar-Sánchez M. E., Serrano-Cruz V., VidalAbeijón I., Martínez-Monzonís M. A., Mazón-Ramos P., Pedreira M., González-Juanatey J. R., Lage R. Transforming cardiotoxicity detection in cancer therapies: the promise of microRNAs as precision biomarkers. International Journal of Molecular Sciences. 2024; 25 (22); 11910. doi: 10.3390/ijms252211910.Alexandraki A., Papageorgiou E., Zacharia M., Keramida K., Papakonstantinou A., Cipolla C. M., Tsekoura D., Naka K., Mazzocco K., Mauri D., Tsiknakis M., Manikis G. C., Marias K., Marcou Y., Kakouri E., Konstantinou I., Daniel M., Galazi M., Kampouroglou E., Ribnikar D., Brown C., Karanasiou G., Antoniades A., Fotiadis D., Filippatos G., Constantinidou A. New insights in the era of clinical biomarkers as potential predictors of systemic therapy-induced cardiotoxicity in women with breast cancer: a systematic review // Cancers. 2023. Vol. 15, No. 13. Art. 3290. doi: 10.3390/cancers15133290.Alexandraki A., Papageorgiou E., Zacharia M., Keramida K., Papakonstantinou A., Cipolla C. M., Tsekoura D., Naka K., Mazzocco K., Mauri D., Tsiknakis M., Manikis G. C., Marias K., Marcou Y., Kakouri E., Konstantinou I., Daniel M., Galazi M., Kampouroglou E., Ribnikar D., Brown C., Karanasiou G., Antoniades A., Fotiadis D., Filippatos G., Constantinidou A. New insights in the era of clinical biomarkers as potential predictors of systemic therapy-induced cardiotoxicity in women with breast cancer: a systematic review. Cancers. 2023; 15 (13); 3290. doi: 10.3390/cancers15133290.Lakhani H. V., Pillai S. S., Zehra M., Dao B., Tirona M. T., Thompson E., Sodhi K. Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer // Scientific Reports. 2021. Vol. 11. Art. 7954. doi: 10.1038/s41598-021-87209-8. PMID: 33846495. PMCID: PMC8041906.Lakhani H. V., Pillai S. S., Zehra M., Dao B., Tirona M. T., Thompson E., Sodhi K. Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer. Scientific Reports. 2021; 11; 7954. doi: 10.1038/s41598-021-87209-8. PMID: 33846495. PMCID: PMC8041906.Dong R., Zhang M., Hu Q., Zheng S., Soh A., Zheng Y., Yuan H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review) // International Journal of Molecular Medicine. 2018. Vol. 41, no. 2. P. 599–614. doi: 10.3892/ijmm.2017.3311.Dong R., Zhang M., Hu Q., Zheng S., Soh A., Zheng Y., Yuan H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). International Journal of Molecular Medicine. 2018; 41 (2): 599–614. doi: 10.3892/ijmm.2017.3311.Sharma U. C., Pokharel S., van Brakel T. J., van Berlo J. H., Cleutjens J. P., Schroen B., André S., Crijns H. J., Gabius H. J., Maessen J., Pinto Y. M. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction // Circulation. 2004. Vol. 110, no. 19. P. 3121–3128. doi: 10.1161/01.CIR.0000147181.65298.4D.Sharma U. C., Pokharel S., van Brakel T. J., van Berlo J. H., Cleutjens J. P., Schroen B., André S., Crijns H. J., Gabius H. J., Maessen J., Pinto Y. M. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110 (19): 3121–3128. doi: 10.1161/01.CIR.0000147181.65298.4D.Srivatsan V., George M., Shanmugam E. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? // European Journal of Preventive Cardiology. 2015. Vol. 22, no. 9. P. 1096–1110. doi: 10.1177/2047487314552797.Srivatsan V., George M., Shanmugam E. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? European Journal of Preventive Cardiology. 2015; 22 (9): 1096–1110. doi: 10.1177/2047487314552797.Chen A., Hou W., Zhang Y., Chen Y., He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis // International Journal of Cardiology. 2015. Vol. 182. P. 168–170. doi: 10.1016/j.ijcard.2014.12.137.Chen A., Hou W., Zhang Y., Chen Y., He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. International Journal of Cardiology. 2015; 182: 168–170. doi: 10.1016/j.ijcard.2014.12.137.Poręba M., Gać P., Usnarska-Zubkiewicz L., Pilecki W., Kuliczkowski K., Mazur G., Sobieszczańska M., Poręba R. The analysis of the parameters of 24-hr ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation // Annals of Noninvasive Electrocardiology. 2018. Vol. 23, no. 4. Art. e12534. doi: 10.1111/anec.12534.Poręba M., Gać P., Usnarska-Zubkiewicz L., Pilecki W., Kuliczkowski K., Mazur G., Sobieszczańska M., Poręba R. The analysis of the parameters of 24-hr ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation. Annals of Noninvasive Electrocardiology. 2018; 23 (4): e12534. doi: 10.1111/anec.12534.Spînu Ș., Cismaru G., Boarescu P. M., Istratoaie S., Negru A. G., Lazea C., Căinap S. S., Iacob D., Grosu A. I., Saraci G., Burz C., Cismaru A. C. ECG markers of cardiovascular toxicity in adult and pediatric cancer treatment // Disease Markers. 2021. Art. 6653971. doi: 10.1155/2021/6653971.Spînu Ș., Cismaru G., Boarescu P. M., Istratoaie S., Negru A. G., Lazea C., Căinap S. S., Iacob D., Grosu A. I., Saraci G., Burz C., Cismaru A. C. ECG markers of cardiovascular toxicity in adult and pediatric cancer treatment. Disease Markers. 2021; 6653971. doi: 10.1155/2021/6653971.Miller W. P., Shanley R., Dorostkar P. Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center // Bone Marrow Transplantation. 2015. Vol. 50, no. 7. P. 954–960. doi: 10.1038/bmt.2015.64.Miller W. P., Shanley R., Dorostkar P. Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center. Bone Marrow Transplantation. 2015; 50 (7): 954–960. doi: 10.1038/bmt.2015.64.Васюк Ю. А., Гендлин Г. Е., Емелина Е. И., Шупенина Е. Ю., Баллюзек М. Ф., Баринова И. В., Виценя М. В., Давыдкин И. Л., Дундуа Д. П., Дупляков Д. В., Затейщиков Д. А., Золотовская И. А., Конради А. О., Лопатин Ю. М., Моисеева О. М., Недогода С. В., Недошивин А. О., Никитин И. Г., Полтавская М. Г., Потиевская В. И., Репин А. Н., Сумин А. Н., Зотова Г. А., Тумян Г. С., Шляхто Е. В., Хатьков И. Е., Якушин С. С., Беленков Ю. Н. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии // Российский кардиологический журнал. 2021. Т. 26, № 9. С. 4703. doi: 10.15829/1560-4071-2021-4703.Vasyuk Yu. A., Gendlin G. E., Emelina E. I., et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Rossiiskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26 (9): 4703. doi: 10.15829/1560-4071-2021-4703 (In Russ.).Watanabe M., Yakushijin K., Tanaka H., Chijiki R., Saeki M., Hirakawa Y., Takakura H., Usui Y., Ichikawa H., Sakai R., Matsumoto S., Nagao S., Mizutani Y., Kurata K., Kitao A., Miyata Y., Saito Y., Kawamoto S., Yamamoto K., Ito M., Matsuoka H., Minami H. Global longitudinal strain is superior to ejection fraction for long-term follow-up after allogeneic hematopoietic stem cell transplantation // eJHaem. 2022. Vol. 4, no. 1. P. 192–198. doi: 10.1002/jha2.586.Watanabe M., Yakushijin K., Tanaka H., Chijiki R., Saeki M., Hirakawa Y., Takakura H., Usui Y., Ichikawa H., Sakai R., Matsumoto S., Nagao S., Mizutani Y., Kurata K., Kitao A., Miyata Y., Saito Y., Kawamoto S., Yamamoto K., Ito M., Matsuoka H., Minami H. Global longitudinal strain is superior to ejection fraction for long-term follow-up after allogeneic hematopoietic stem cell transplantation. eJHaem. 2022; 4 (1): 192–198. doi: 10.1002/jha2.586.Thavendiranathan P., Poulin F., Lim K. D., Plana J. C., Woo A., Marwick T. H. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review // Journal of the American College of Cardiology. 2014. Vol. 63, no. 25, Pt A. P. 2751–2768. doi: 10.1016/j.jacc.2014.01.073.Thavendiranathan P., Poulin F., Lim K. D., Plana J. C., Woo A., Marwick T. H. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. Journal of the American College of Cardiology. 2014; 63 (25), pt. A: 2751–2768. doi: 10.1016/j.jacc.2014.01.073.Oikonomou E. K., Kokkinidis D. G., Kampaktsis P. N., Amir E. A., Marwick T. H., Gupta D., Thavendiranathan P. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis // JAMA Cardiology. 2019. Vol. 4. P. 1007–1018. doi: 10.1001/jamacardio.2019.2952.Oikonomou E. K., Kokkinidis D. G., Kampaktsis P. N., Amir E. A., Marwick T. H., Gupta D., Thavendiranathan P. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiology. 2019; 4: 1007–1018. doi: 10.1001/jamacardio.2019.2952.Voigt J. U., Pedrizzetti G., Lysyansky P., Marwick T. H., Houle H., Baumann R., Pedri S., Ito Y., Abe Y., Metz S., Song J. H., Hamilton J., Sengupta P. P., Kolias T. J., d'Hooge J., Aurigemma G. P., Thomas J. D., Badano L. P. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging // European Heart Journal – Cardiovascular Imaging. 2015. Vol. 16, no. 1. P. 1–11.Voigt J. U., Pedrizzetti G., Lysyansky P., Marwick T. H., Houle H., Baumann R., Pedri S., Ito Y., Abe Y., Metz S., Song J. H., Hamilton J., Sengupta P. P., Kolias T. J., d'Hooge J., Aurigemma G. P., Thomas J. D., Badano L. P. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. European Heart Journal – Cardiovascular Imaging. 2015; 16 (1): 1–11.Park J. J., Park J. B., Park J. H., Cho G. Y. Global longitudinal strain to predict mortality in patients with acute heart failure // Journal of the American College of Cardiology. 2018. Vol. 71, no. 18. P. 1947–1957.Park J. J., Park J. B., Park J. H., Cho G. Y. Global longitudinal strain to predict mortality in patients with acute heart failure. Journal of the American College of Cardiology. 2018; 71 (18): 1947–1957.Wei X., Lin L., Zhang G., Zhou X. Cardiovascular magnetic resonance imaging in the early detection of cardiotoxicity induced by cancer therapies // Diagnostics. 2022. Vol. 12, no. 8. Art. 1846. doi: 10.3390/diagnostics12081846.Wei X., Lin L., Zhang G., Zhou X. Cardiovascular magnetic resonance imaging in the early detection of cardiotoxicity induced by cancer therapies. Diagnostics. 2022; 12 (8); 1846. doi: 10.3390/diagnostics12081846.Omidi A., Weiss E., Trankle C. R., Rosu-Bubulac M., Wilson J. S. Quantitative assessment of radiotherapy-induced myocardial damage using MRI: a systematic review // Cardio-Oncology. 2023. Vol. 9, no. 1. Art. 24. doi: 10.1186/s40959-023-00175-0.Omidi A., Weiss E., Trankle C. R., Rosu-Bubulac M., Wilson J. S. Quantitative assessment of radiotherapy-induced myocardial damage using MRI: a systematic review. Cardio-Oncology. 2023; 9 (1); 24. doi: 10.1186/s40959-023-00175-0.Vaitiekiene A., Kulboke M., Bieseviciene M., Jankauskas A., Bartnykaite A., Rinkuniene D., Strazdiene I., Lidziute E., Jankauskaite D., Gaidamavicius I., Bucius P., Lapinskas T., Gerbutavicius R., Juozaityte E., Vaskelyte J. J., Vaitiekus D., Sakalyte G. T1 mapping in cardiovascular magnetic resonance a marker of diffuse myocardial fibrosis in patients undergoing hematopoietic stem cell transplantation // Journal of Personalized Medicine. 2024. Vol. 14, no. 4. Art. 412. doi: 10.3390/jpm14040412.Vaitiekiene A., Kulboke M., Bieseviciene M., Jankauskas A., Bartnykaite A., Rinkuniene D., Strazdiene I., Lidziute E., Jankauskaite D., Gaidamavicius I., Bucius P., Lapinskas T., Gerbutavicius R., Juozaityte E., Vaskelyte J. J., Vaitiekus D., Sakalyte G. T1 mapping in cardiovascular magnetic resonance a marker of diffuse myocardial fibrosis in patients undergoing hematopoietic stem cell transplantation. Journal of Personalized Medicine. 2024; 14 (4); 412. doi: 10.3390/jpm14040412.Paiman E. H. M., Louwerens M., Bresters D., Westenberg J. J. M., Tao Q., van der Geest R. J., Lankester A. C., Roest A. A. W., Lamb H. J. Late effects of pediatric hematopoietic stem cell transplantation on left ventricular function, aortic stiffness and myocardial tissue characteristics // Journal of Cardiovascular Magnetic Resonance. 2019. Vol. 21. Art. 6. doi: 10.1186/s12968-018-0513-4.Paiman E. H. M., Louwerens M., Bresters D., Westenberg J. J. M., Tao Q., van der Geest R. J., Lankester A. C., Roest A. A. W., Lamb H. J. Late effects of pediatric hematopoietic stem cell transplantation on left ventricular function, aortic stiffness and myocardial tissue characteristics. Journal of Cardiovascular Magnetic Resonance. 2019; 21; 6. doi: 10.1186/s12968-018-0513-4.Plana J., Thavendiranathan P., Bucciarelli-Ducci C., Lancellotti P. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient // JACC: Cardiovascular Imaging. 2018. Vol. 11, no. 8. P. 1173– 1186. doi: 10.1016/j.jcmg.2018.06.003.Plana J., Thavendiranathan P., Bucciarelli-Ducci C., Lancellotti P. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC: Cardiovascular Imaging. 2018; 11 (8): 1173–1186. doi: 10.1016/j.jcmg.2018.06.003.Becker M. M. C., Arruda G. F. A., Berenguer D. R. F., Buril R. O., Cardinale D., Brandão S. C. S. Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker // Cardio-Oncology. 2023. Vol. 9, no. 1. Art. 17. doi: 10.1186/s40959-023-00161-6.Becker M. M. C., Arruda G. F. A., Berenguer D. R. F., Buril R. O., Cardinale D., Brandão S. C. S. Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker. Cardio-Oncology. 2023; 9 (1); 17. doi: 10.1186/s40959-023-00161-6.Kim J., Feller E. D., Chen W., Liang Y., Dilsizian V. FDG PET/CT for early detection and localization of left ventricular assist device infection: impact on patient management and outcome // JACC: Cardiovascular Imaging. 2019. Vol. 12, no. 4. P. 722–729. doi: 10.1016/j.jcmg.2018.01.024.Kim J., Feller E. D., Chen W., Liang Y., Dilsizian V. FDG PET/CT for early detection and localization of left ventricular assist device infection: impact on patient management and outcome. JACC: Cardiovascular Imaging. 2019; 12 (4): 722–729. doi: 10.1016/j.jcmg.2018.01.024.Simoni L. J. C., Brandão S. C. S. New imaging methods for detection of drug-induced cardiotoxicity in cancer patients // Current Cardiovascular Imaging Reports. 2017. Vol. 10, no. 6. Art. 1–11. doi: 10.1007/s12410-0179415-3.Simoni L. J. C., Brandão S. C. S. New imaging methods for detection of drug-induced cardiotoxicity in cancer patients. Current Cardiovascular Imaging Reports. 2017; 10 (6); 1–11. doi: 10.1007/s12410-017-9415-3.Mahabadi A. A., Rischpler C. Cardiovascular imaging in cardio-oncology // Journal of Thoracic Disease. 2018. Vol. 10, suppl. 35. P. S4351–S4366. doi: 10.21037/jtd.2018.10.92.Mahabadi A. A., Rischpler C. Cardiovascular imaging in cardio-oncology. Journal of Thoracic Disease. 2018; 10, suppl. 35: S4351–S4366. doi: 10.21037/jtd.2018.10.92.Wetscherek M. T. A., McNaughton E., Majcher V., Wetscherek A., Sadler T. J., Alsinbili A., Teh W. H., Moore S. D., Patel N., Smith W. P. W., Krishnan U. Incidental coronary artery calcification on non-gated CT thorax correlates with risk of cardiovascular events and death // European Radiology. 2023. Vol. 33, no. 7. P. 4723–4733. doi: 10.1007/s00330-023-09428-z.Wetscherek M. T. A., McNaughton E., Majcher V., Wetscherek A., Sadler T. J., Alsinbili A., Teh W. H., Moore S. D., Patel N., Smith W. P. W., Krishnan U. Incidental coronary artery calcification on non-gated CT thorax correlates with risk of cardiovascular events and death. European Radiology. 2023; 33 (7): 4723–4733. doi: 10.1007/s00330-023-09428-z.Lehmann N., Erbel R., Mahabadi A. A., Rauwolf M., Möhlenkamp S., Moebus S., Kälsch H., Budde T., Schmermund A., Stang A., Führer-Sakel D., Weimar C., Roggenbuck U., Dragano N., Jöckel K. H.; Heinz Nixdorf Recall Study Investigators. Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR study (Heinz Nixdorf Recall) // Circulation. 2018. Vol. 137, no. 7. P. 665–679. doi: 10.1161/CIRCULATIONAHA.116.027034.Lehmann N., Erbel R., Mahabadi A. A., Rauwolf M., Möhlenkamp S., Moebus S., Kälsch H., Budde T., Schmermund A., Stang A., Führer-Sakel D., Weimar C., Roggenbuck U., Dragano N., Jöckel K. H.; Heinz Nixdorf Recall Study Investigators. Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR study (Heinz Nixdorf Recall). Circulation. 2018; 137 (7): 665–679. doi: 10.1161/CIRCULATIONAHA.116.027034.Patel S., Franco F. X., McDonald M., Rivera C., Perez-Villa B., Collier P., Moudgil R., Gupta N., Sadler D. B. Use of computed tomography coronary calcium score for prediction of cardiovascular events in cancer patients: a retrospective cohort analysis // Cardio-Oncology. 2024. Vol. 10, no. 1. Art. 1. doi: 10.1186/s40959-023-00196-9.Patel S., Franco F. X., McDonald M., Rivera C., Perez-Villa B., Collier P., Moudgil R., Gupta N., Sadler D. B. Use of computed tomography coronary calcium score for prediction of cardiovascular events in cancer patients: a retrospective cohort analysis. Cardio-Oncology. 2024; 10 (1); 1. doi: 10.1186/s40959-023-00196-9.Borowiec A., Ozdowska P., Rosinska M., Zebrowska A. M., Jagiello-Gruszfeld A., Jasek S., Waniewska J., Kotowicz B., Kosela-Paterczyk H., Lampka E., Pogoda K., Cieszanowski A., Nowecki Z., Walewski J. Coronary artery calcium score and other risk factors in patients at moderate and high risk of cancer therapy-related cardiovascular toxicity // Cardio-Oncology. 2024. Vol. 10, no. 1. Art. 64. doi: 10.1186/s40959-024-00266-6.Borowiec A., Ozdowska P., Rosinska M., Zebrowska A. M., Jagiello-Gruszfeld A., Jasek S., Waniewska J., Kotowicz B., Kosela-Paterczyk H., Lampka E., Pogoda K., Cieszanowski A., Nowecki Z., Walewski J. Coronary artery calcium score and other risk factors in patients at moderate and high risk of cancer therapy-related cardiovascular toxicity. Cardio-Oncology. 2024; 10 (1); 64. doi: 10.1186/s40959-024-00266-6.

The authors declare that there are no conflicts of interest present.